Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2366-1089
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer ; volume:11 ; number:1 ; day:16 ; month:1 ; year:2023 ; pages:111-128 ; date:3.2023
Oncology and Therapy ; 11, Heft 1 (16.1.2023), 111-128, 3.2023
- Urheber
-
Barbier, Sandrine
Beaufils, Benjamin
Miguel, Ricardo de
Reyre, Melissa
Meitour, Yannick Le
Lortie, Andreanne
Boisferon, Marc Hillairet de
Chaumeron, Sophie
Espirito, Anne
Fossati, Lina
Lagarde, Pauline
Klinz, Stephan
Thiagalingam, Arunthathi
Lezmi, Stéphane
Meyer-Losic, Florence
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40487-022-00215-2
- URN
-
urn:nbn:de:101:1-2023041921084024406260
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Barbier, Sandrine
- Beaufils, Benjamin
- Miguel, Ricardo de
- Reyre, Melissa
- Meitour, Yannick Le
- Lortie, Andreanne
- Boisferon, Marc Hillairet de
- Chaumeron, Sophie
- Espirito, Anne
- Fossati, Lina
- Lagarde, Pauline
- Klinz, Stephan
- Thiagalingam, Arunthathi
- Lezmi, Stéphane
- Meyer-Losic, Florence
- SpringerLink (Online service)
Ähnliche Objekte (12)
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report
Light‐Triggered Cancer Cell Specific Targeting and Liposomal Drug Delivery in a Zebrafish Xenograft Model
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report
Light‐Triggered Cancer Cell Specific Targeting and Liposomal Drug Delivery in a Zebrafish Xenograft Model
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report